American Vanguard Corporation — 2012 Form 10-K
Business and period: Specialty chemical manufacturer and distributor serving agricultural and commercial markets, including crop protection, human and animal health products. The company reports one operating segment. This annual filing covers the year ended December 31, 2012; fourth-quarter figures are also shown below. Unless stated otherwise, dollar amounts are in millions.
Financial performance and liquidity
| Metric | 2012 | 2011 |
|---|---|---|
| Net sales | $366.2 | $301.1 |
| Gross profit / gross margin | $161.1 / 44% | $123.1 / 41% |
| Operating income | $59.3 | $39.2 |
| Income before taxes | $56.9 | $35.2 |
| Net income attributable to American Vanguard | $36.9 | $22.1 |
| Diluted earnings per share | $1.28 | $0.79 |
| Cash from operating activities | $40.4 | $39.3 |
| Capital expenditures | $17.6 | $6.3 |
| Cash at year-end | $38.5 | $35.1 |
| Working capital | $108.6 | $104.7 |
| Total indebtedness | $52.4 | $66.4 |
Sales rose 22% year over year, led by crop insecticides and non-crop products. Insecticide sales increased 41%; crop sales grew 21% and non-crop sales 26%. Herbicide sales declined slightly. Gross margin improved three percentage points, with management citing product mix, average selling-price increases of about 5%, and raw-material cost increases of about 2%. Operating expenses increased $18.0 million to $101.8 million, mainly from higher general and administrative, freight, research, product-development and regulatory costs. Operating margin was approximately 16.2% versus 13.0% in 2011.
Fourth quarter: Sales were $104.3 million, gross profit $45.8 million, net income attributable to American Vanguard $11.3 million, and diluted EPS $0.39. For the comparable 2011 quarter, sales were $81.8 million, gross profit $33.9 million, net income $6.4 million, and diluted EPS $0.23.
Operating cash flow was slightly higher than in 2011. Investing used $21.1 million, primarily for $17.6 million of capital spending and a $3.5 million technology license; financing used $16.4 million, including debt repayments and $6.1 million of dividends. Inventory increased $16.9 million to $88.0 million, which management attributed to expected early-season demand and year-end receipt of the Impact herbicide. Total debt included $46.0 million of term loans and $6.4 million of acquisition-related notes; $16.2 million was classified as current. The company reported compliance with its credit covenants, no revolver borrowings during 2012, and up to $75 million of additional borrowing capacity under covenant limits. Debt is secured by substantially all company assets and the credit facility matures in January 2016.
Changes, outlook, risks and unusual items
- Drivers and operating conditions: Management attributed demand gains to strong crop commodity prices, increased corn acreage, pest pressure and adoption of conventional chemistry in integrated pest management. Severe 2012 drought reduced corn yields and damaged cotton acreage, although management said it did not materially affect demand for granular soil insecticides applied at planting. Cotton defoliant and insecticide sales benefited from more favorable conditions in some regions.
- Products and expansion: The company formed Envance with TyraTech in November 2012, holding a 60% interest, to develop and commercialize pesticide products and technologies. Initial sales of organic aerosol products began before year-end. The company also entered a 10-year technology licensing arrangement. No quantified 2013 earnings or sales guidance is provided; management said liquidity should be adequate for operating and capital needs for at least 12 months, while significant growth could require use of credit availability or additional financing.
- Customer and supply concentration: Three distributors accounted for 53% of 2012 sales (24%, 19% and 10%). The company also depends on certain sole-source suppliers for active ingredients or finished products; supply shortfalls or supplier changes could constrain sales.
- Regulatory, environmental and legal exposure: Most products require ongoing U.S. and foreign registrations and supporting scientific data. The company spent $17.8 million on required data gathering in 2012. At its Commerce, California facility, further investigation and possible remediation remain uncertain; the company could not determine whether remediation was probable or reasonably estimate its cost and recorded no contingency. Approximately 100 DBCP-related lawsuits name AMVAC; the company recorded no contingency for these matters because it did not consider loss probable or reasonably estimable. A Brazilian regulatory citation carries a recorded $150,000 reserve, with management estimating a probable loss of $150,000–$200,000.
- Other items: The 2012 dividend was $0.22 per share, including a $0.10 special dividend. The 2011 comparative financial statements were revised for deferred-tax presentation and reversal of a sales/cost-of-sales gross-up; the company stated the revisions did not affect 2011 equity, gross margin, net income, EPS or operating cash flow and were not material. No impairment losses were recorded in 2012.
Key facts for investors to verify
- Whether demand and improved margins persisted after the unusually strong 2012 crop-protection market, and how drought and seasonal conditions affected subsequent periods.
- Whether increased inventory converted to sales and cash, and whether customer programs, receivables and working-capital needs remained manageable.
- Supplier continuity and progress in transferring or securing production for sole-source products.
- Developments in product registrations, Commerce-site remediation planning, the DBCP cases and the Brazilian citation.
- Debt repayment, covenant headroom and financing needs if growth or capital spending accelerates.